Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9169172 | 0.95 | CA12 (0.51) | CA12CA1CA2CA9CA7 | |
| SCHEMBL2432171 | 0.89 | CA12 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL13527258 | 0.84 | CA12 (0.66) | CA12CA1CA2CA9CA7 | |
| SCHEMBL6378122 | 0.83 | CA12 (0.70) | CA12CA1CA2CA9CA7 | |
| SCHEMBL9453006 | 0.82 | TSHR (0.64) | CA12CA1CA2CA9CA7 | |
| SCHEMBL10460537 | 0.81 | CA12 (0.53) | CA12CA1CA2CA9CA7 | |
| SCHEMBL28049790 | 0.81 | CA12 (0.45) | CA12CA1CA2CA9CA7 | |
| SCHEMBL18088503 | 0.81 | GPR119 (0.52) | CA12CA1CA2CA9CA7 | |
| SCHEMBL11615899 | 0.80 | KCNA3 (0.55) | TSHRL3MBTL1GAA | |
| SCHEMBL14080761 | 0.80 | CA12 (0.56) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | CA12 2010/4885CA1 1372/4885CA2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.